Your browser doesn't support javascript.
loading
TAVI in Patients with Mitral Annular Calcification and/or Mitral Stenosis.
Schaefer, Andreas; Sarwari, Harun; Schofer, Niklas; Schneeberger, Yvonne; Westermann, Dirk; Schoen, Gerhard; Blankenberg, Stefan; Reichenspurner, Hermann; Schäfer, Ulrich; Conradi, Lenard.
  • Schaefer A; Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.
  • Sarwari H; Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.
  • Schofer N; Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Schneeberger Y; Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.
  • Westermann D; Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Schoen G; Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Blankenberg S; Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Reichenspurner H; Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.
  • Schäfer U; Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Conradi L; Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.
Thorac Cardiovasc Surg ; 69(5): 428-436, 2021 Aug.
Article en En | MEDLINE | ID: mdl-32114689
ABSTRACT

BACKGROUND:

We herein aimed for analysis of influence of mitral annular calcification (MAC) and mitral stenosis (MS) on outcomes in transcatheter aortic valve implantation (TAVI).

METHODS:

Between 11/2009 and 06/2017, 1,058 patients underwent TAVI in the presence of concomitant MAC or MS at our center. Subgroups were built and multivariate logistic regression, COX regression, Kaplan-Meier survival analyses, and receiver operating characteristics method were performed.

RESULTS:

Thirty-day mortality was 7.5% (79/1,058) with highest mortality in patients severe MS (MAC 3.4% vs. mild MS 5.9% vs. moderate MS 15.0% vs. severe MS 72.7%; p < 0.001). Moderate-to-severe MS (odds ratio [OR] 7.75, confidence interval [CI] 3.94-16.26, p < 0.001), impaired left ventricular ejection fraction (OR 1.38, CI 1.10-1.72, p < 0.01), and coronary artery disease (OR 1.36, CI 1.11-1.67, p < 0.01) were predictive of 30-day survival. Left ventricular systolic/end-diastolic pressure drop of <59.5 mm Hg / <19.5 mm Hg was associated with increased mortality.

CONCLUSIONS:

TAVI in the presence of MAC and mild MS is associated with acceptable acute outcomes but should be considered high-risk procedures in patients with moderate and especially those with severe MS. Our results suggest adverse hemodynamics after TAVI with concomitant MS, which may be caused by underfilling of the left ventricle leading to low-cardiac output.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Válvula Aórtica / Estenosis de la Válvula Aórtica / Calcinosis / Reemplazo de la Válvula Aórtica Transcatéter / Hemodinámica / Válvula Mitral / Estenosis de la Válvula Mitral Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Válvula Aórtica / Estenosis de la Válvula Aórtica / Calcinosis / Reemplazo de la Válvula Aórtica Transcatéter / Hemodinámica / Válvula Mitral / Estenosis de la Válvula Mitral Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Año: 2021 Tipo del documento: Article